YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Innate Pharma S.A. Sponsored ADR (IPHA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered…
Innate Pharma S.A. (NASDAQ:IPHA) reported a €19.6 million first-half net loss on September 17, following the closing of its lacutamab partnership with Sobi a day earlier. The closing triggered a $75 million upfront payment. Management proj…
Image source: The Motley Fool. DATE Thursday, Sept. 17, 2026, at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer-Jonathan E. Dickinson Chief Medical Officer-Sonia Quaratino Chief Operating Officer-Yannis Morel Chief Financial Officer-F…
Key Points Interested in Innate Pharma S.A. Sponsored ADR? Here are five stocks we like better. Innate Pharma strengthened its finances through a Sobi partnership for lacutamab, including a $75 million upfront payment, and a €30 million eq…
* Innate Pharma press release [https://seekingalpha.com/pr/20654600-innate-pharma-reports-first-half-2026-business-update-and-financial-results] (IPHA [https://seekingalpha.com/symbol/IPHA]): 1H GAAP EPS of -€0.21 * Revenue of €5.7M (+16.3…
New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing completed to primarily support IPH4502 and pr…
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership…
MARSEILLE, France, September 10, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September…
MARSEILLE, France, September 02, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patient…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Swedish Orphan Biovitrum Stock Is Back In Focus Swedish Orphan Biovitrum (OM:SOBI) has drawn fresh attention after…
(RTTNews) - Shares of Innate Pharma S.A. (IPHA), a clinical-stage company, surge over 25% after the company announced a strategic partnership with Swedish Orphan Biovitrum AB (SOBI.ST) to enable initiation of the TELLOMAK-3 confirmatory Ph…
(RTTNews) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma, a key step toward…
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to ena…
MARSEILLE, France, August 10, 2026--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a…
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty s…
DelveInsight Business Research LLP The peripheral T-cell lymphoma treatment market is witnessing steady growth, primarily driven by the increasing incidence, leading to an increased patient population, which fuels the ongoing treatment dem…
This article first appeared on GuruFocus. Release Date: March 26, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Innate Pharma SA (NASDAQ:IPHA) has received FDA cle…
Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty struct…
A downtrend has been apparent in Innate Pharma S.A. Sponsored ADR (IPHA) lately. While the stock has lost 12.1% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This co…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Outperf…
This article first appeared on GuruFocus. Total Revenue: EUR4.9 million, primarily from collaborations with AstraZeneca and Sanofi, and governmental funding for research expenditures. Operating Expenses: EUR30.3 million, with EUR20.5 milli…
* Innate Pharma S.A. press release [https://seekingalpha.com/pr/20234909-innate-pharma-reports-first-half-2025-business-update-and-financial-results] (OTCPK:IPHYF [https://seekingalpha.com/symbol/IPHYF]): 1H GAAP EPS of -€0.25. * Revenue o…
September S&P 500 E-Mini futures (ESU25) are up +0.01%, andSeptember Nasdaq 100 E-Mini futures (NQU25) are down -0.04% this morning as investors refrain from making any big bets ahead of a highly anticipated Federal Reserve interest rate d…
September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are up +0.01%, and September Nasdaq 100 E-Mini futures (NQU25 [https://www.barchart.com/futures/quotes/NQU25/overview]) are down -0.04% this morning a…
(RTTNews) - Innate Pharma S.A. (IPHA, IPH.PA), a French biotechnology firm, on Wednesday reported a narrower first-half net loss mainly aided by reduced expenses, amid weak revenues. Further, Innate Pharma said it plans to prioritize its i…
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion…
Revenue and Other Income: 20.1 million in 2024, primarily from collaboration licensing agreements (12.6 million) and a research tax credit (7.5 million). Operating Expenses: 71.7 million in 2024, with 73% related to R&D. General and Admini…
Innate Pharma S.A. (NASDAQ:IPHA) Q4 2023 Earnings Call Transcript March 21, 2024 Innate Pharma S.A. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: At this time, I…
In this article, we discuss the 15 undervalued defensive stocks for 2024. To skip the detailed overview of the market and defensive stocks, go directly to the 5 Undervalued Defensive Stocks For 2024. Defensive stocks are shares of companie…
Innate Pharma S.A. (NASDAQ:IPHA) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Thank you for standing by, and welcome to the Innate Pharma Third Quarter 2023 Financial Results and Business Update. I would now like to welcome…
Partner Sanofi advances SAR’514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint research collaboration between Innate Pharma and Sanofi, to first-in-human clinical trial in relapsed/refractory Multiple Myeloma…
MARSEILLE, France, July 07, 2023--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AM…
Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE,…
Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chemotherapy in early stage lung cancer IPH5201 is developed in collaboration with AstraZeneca MARSEILLE,…
Efficacy results presented at the 17th International Conference on Malignant Lymphoma, have been analysed according to updated lymph node involvement classification and confirm clinical activity and favorable safety profile of lacutamab in…
Efficacy results of lacutamab in Mycosis Fungoides according to updated lymph node classification in the TELLOMAK Phase 2 study in advanced cutaneous T cell lymphomas MARSEILLE, France, June 12, 2023--(BUSINESS WIRE)--Innate Pharma SA (Eur…